Posts Tagged ‘alternative medicine’

RSS

May 1st, 2015

Red Yeast Rice: Let’s Lower Cholesterol with Unknown Amounts of a Statin

Anthony Pearson wonders why some patients would choose unregulated “natural” cholesterol-lowering dietary supplements over safe and effective prescription statins.


July 17th, 2014

Clinical Events vs. Quality of Life: An Insider’s View of TACT

TACT investigator Gervasio Lamas provides perspective on two new TACT papers that appear to have contradictory results.


November 19th, 2013

TACT Substudy Suggests Possible Strong Benefit for Chelation in Diabetics

One year ago the results of the TACT trial were published in JAMA, sparking an enormous controversy over the propriety of publishing a trial suggesting that chelation therapy might be beneficial in people with cardiovascular disease. Chelation therapy has long been a staple of alternative medicine, but until the publication of TACT it had received […]


April 9th, 2013

The TACT Investigators Respond to Questions

, , , , and

The publication in JAMA of the NIH’s Trial to Assess Chelation Therapy (TACT) has reignited a heated debate about the trial. The TACT investigators have generously agreed to respond to questions posed by Harlan Krumholz.


March 26th, 2013

Controversial NIH Chelation Trial Published in JAMA

Final results of the troubled NIH-sponsored Trial to Assess Chelation Therapy (TACT) testing chelation therapy for coronary disease have now been published in JAMA. Last November, when the preliminary results were presented at the American Heart Association meeting, the positive finding in favor of chelation therapy surprised many observers, though the investigators and senior AHA representatives expressed considerable caution […]


November 6th, 2012

What Tack to Take in Thinking about TACT?

A fellow encounters a little-understood intervention and startling study results; can informal discussions with senior faculty at AHA provide insight?


November 4th, 2012

NIH Trial Gives Surprising Boost to Chelation Therapy

The TACT trial finds that cardiovascular endpoints were lower with chelation therapy than placebo in patients with prior MI, but trial investigators and others have expressed considerable caution about the proper interpretation of the results.